ThermoDox heat-activated liposome: Interim Phase I/II data

Interim data from 4 evaluable patients in the open-label, dose-escalation, U.S. Phase I/II DIGNITY trial showed that ThermoDox in combination with microwave hyperthermia was well tolerated at 40 mg/m 2, with no serious adverse events or dose-limiting toxicities reported. All patients had at least a partial response. Data were presented at the Breast Cancer Symposium in Washington. Celsion also said enrollment in the 50 mg/m 2 ThermoDox cohort has been completed. ...